Disease & disorder

DICER1-related tumor predisposition

MONDO:0100216

Pathogenic germline variation in DICER1 confers an autosomal dominant predisposition to tumor formation at multiple primary sites, including pleuropulmonary blastoma, pulmonary cysts, thyroid gland neoplasia, ovarian tumors, and cystic nephroma. Other syndromic features such as macrocephaly have been described.

Clinical trials2

Recruiting2

Drug concepts studied0

Synonyms7

Disease research snapshot

CureCurrent currently links 2 distinct registered clinical trials to DICER1-related tumor predisposition through its MONDO disease mappings. 2 of those studies have the registry status “recruiting” (100%). These are registry statuses, not availability guarantees, study results or evidence of effectiveness.

The leading sponsor shown in this linked dataset is St. Jude Children's Research Hospital, associated with 1 distinct linked trials. This is a count of records, not a ranking of the sponsor's scientific quality.

The highest-count mapped research city in the current result is Memphis, United States. Only site locations available in the published registry projection are counted; some trial sites may be missing or outdated.

Numbers are derived from CureCurrent's current ClinicalTrials.gov projection and conservative MONDO/RxNorm mappings. See sources, counting rules and limitations and verify eligibility or clinical findings with the original study record.

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.